Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.33 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22112683 | 0.85 | THRB (0.38) | NPC1DGAT1F11MAPT | |
| SCHEMBL15050240 | 0.77 | NPC1 (0.34) | NPC1DGAT1F11MAPTKLKB1 | |
| SCHEMBL25104434 | 0.77 | DGAT1 (0.38) | NPC1DGAT1F2RL1F11KLKB1 | |
| SCHEMBL30725389 | 0.77 | DGAT1 (0.38) | NPC1DGAT1F2RL1KLKB1 | |
| SCHEMBL23294652 | 0.75 | MAPT (0.36) | DGAT1MAPT | |
| SCHEMBL4844103 | 0.75 | NPSR1 (0.36) | NPC1DGAT1F11MAPTKLKB1 | |
| SCHEMBL4552872 | 0.75 | MEN1 (0.39) | NPC1DGAT1F11MAPTKLKB1 | |
| SCHEMBL29749363 | 0.74 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL1244925 | 0.73 | MAPT (0.37) | NPC1DGAT1F11MAPTKLKB1 | |
| SCHEMBL23063215 | 0.73 | NPC1 (0.34) | NPC1F11MAPTKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676931-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BioSplice Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250340575-A1 | 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250206746-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2025-06-26 | — | — | US | disclosed |
| WO-2025137469-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BIOSPLICE THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-119604506-A | 4-Alkoxypyrrolo [2,1-f ] [1,2,4] triazines, preparation and use thereof | 拜斯丽治疗有限公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2024211797-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BIOSPLICE THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20240002391-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2024-01-04 | — | — | US | disclosed |
| WO-2023250156-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340575-A1 | 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK2, DYRK1B | NPC1 4578/4885DGAT1 2428/4885F2RL1 285/4885 |
| US-20240002391-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK2, DYRK1B | NPC1 3433/4885DGAT1 1402/4885F2RL1 399/4885 |
| US-20250206746-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK2, DYRK1B | NPC1 3433/4885DGAT1 1402/4885F2RL1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.